Pancreatic cancer is the 8th most common cause of cancer-related deaths worldwide and the tumor with the poorest prognosis of all solid malignancies. In 1957, it was discovered that Newcastle disease virus (NDV) has oncolytic properties on tumor cells. To study the oncolytic properties of NDV in pancreatic cancer a single dose was administered intravenously in a syngeneic orthotopic tumor model using two different murine pancreatic adenocarcinoma cell lines (DT6606PDA, Panc02). Tumor growth was monitored and immune response was analyzed. A single treatment with NDV inhibited DT6606PDA tumor growth in mice and prevented recurrence for a period of three months. Tumor infiltration and systemic activation of NK cells, cytotoxic and helper T-cells was enhanced. NDV-induced melting of Panc02 tumors until d7 pi, but they recurred displaying unrestricted tumor growth, low immunogenicity and inhibition of tumor-specific immune response. Arrest of DT6606PDA tumor growth and rejection was mediated by activation of NK cells and a specific antitumor immune response via T-cells. Panc02 tumors rapidly decreased until d7 pi, but henceforth tumors characterized by the ability to perform immune-regulatory functions reappeared. Our results demonstrated that NDV-activated immune cells are able to reject tumors provided that an adaptive antitumor immune response can be initiated. However, activated NK cells that are abundant in Panc02 tumors lead to outgrowth of nonimmunogenic tumor cells with inhibitory properties. Our study emphasizes the importance of an adaptive immune response, which is initiated by NDV to mediate long-term tumor surveillance in addition to direct oncolysis.
Introduction
With approximately 250,000 new cases per year worldwide, an incidence which equals prevalence, pancreatic cancer PDAC is one of the most aggressive malignancies, burdened with a dismal prognosis and a limited treatment response to classical chemotherapy. 1 It represents the 8th leading cause of cancer-related deaths worldwide and is projected to be the 2nd leading cause of cancer-related deaths in 2030. 2 Specific anticancer therapies that selectively recognize and lyse malignant cells while sparing healthy cells currently are only scantily available. In the last decades, several studies have been published on the use of oncolytic viruses (OVs) which proliferate specifically in cancer cells. 3, 4 A modified herpes simplex virus (Talimogene laherparepvec, T-VEC) has been approved in 2015 as the first oncolytic virus for use in clinical treatment of melanoma. 5 Newcastle Disease Virus (NDV), the highly virulent pathogen of Newcastle disease belonging to the family of Paramyxoviridae, is a promising candidate for use in virotherapy. 6, 7 NDV selectively replicates in tumor cells and thus destroys these cells, leaving normal cells rather unaffected. Basically, two explanations were put forward for this behavior: First, a considerable number of tumors are known to have acquired defects in antiviral pathways and only respond inadequately to viral infection with IFN type I production; 8 second, tumor cells, in contrast to normal cells, do not undergo apoptosis upon viral infection due to their established resistance and therefore viral replication is enhanced. 9 This in turn makes them a more suitable host for viral replication and promotes spread to surrounding cells. 10 Several preclinical and clinical trials have proven the effectiveness of NDV against tumors without affecting normal cells. [11] [12] [13] As infection of normal cells leads to interferon type I (IFN type I) production which stops viral replication, these cells appear to be unaffected. 14 To date the majority of research in the field of OV therapies aims to design viruses that present a rapid growth in tumor cells and thus the lysis of malignant cells, but neglect the impact of a possible antitumor immune response upon NDV infection. 4 In the last decade, evidence has been accumulating that not only the direct oncolytic effect of NDV but rather the activation of the immune system triggers tumor rejection through a specific or unspecific antitumor immune response. 15 Indeed, contrasting the former thought of the immune system as an impediment for virotherapy, the combination of both direct oncolysis and the induction of an adaptive antitumor immune response might lead to an even more efficient attack of tumors. [16] [17] [18] Because early preclinical studies were often implemented in immunocompromised animals in order to use human cancer cells, NDV-stimulated immune cell response against the tumor was not assessable. 19, 20 Subcutaneous inoculation of tumor cells also distorts observed NDV-mediated effects against the tumor due to an unnatural tumor microenvironment. 20, 21 In this study, we took advantage of a syngeneic orthotopic murine model of pancreatic cancer to characterize the immune response upon infection with a field isolate of NDV, strain R75/98, regarding tumor progression and a possible antitumor immune response in immunocompetent mice in vivo.
Material and Methods

Mice
For all animal experiments, 6-8-week-old male C57BL/6N mice were either purchased from Charles River (Bad Sulzfeld, Germany) or bred under SPF-conditions in the animal facility at the Friedrich-Loeffler-Institut, Greifswald-Insel Riems and housed in a 12-h dark/light cycle with access to standard laboratory chow and water ad libitum according to the European guidelines for laboratory animal housing.
Cell lines, culture, and in vitro infection
Originally, DT6606PDA cells were isolated from a pancreatic ductal adenocarcinoma of a transgenic C57BL/6N mouse carrying the Kras D12G allele. 22 Panc02 cells were chemically generated by Corbett et al. using 3-methylcholanthren (3-MCA). 23 Cells were cultured in RPMI-1640 medium with 10% FCS (fetal calf serum) and 1% antibiotics (PenicillinStreptomycin, all reagents: Gibco, Life Technologies, Frankfurt, Germany) in a humidified incubator at 378C with 5% CO 2 . For re-isolation of Panc02 tumor cells, part of the removed tumor was minced with a scissor in PBS and passed through a cell strainer (BD Bioscience, San Jose, CA). After centrifugation, cells were suspended in RPMI-1640 medium with 10% FCS and 1% antibiotics. Outgrowing adherent tumor cells were passaged 2 times before using in flow cytometric and Western Blot analysis. For determination of MHC I, FoxP3, and Rae-1d as well as secretion of TGF-b, cells were infected with NDV R75/98 with an MOI of 0.5 and cultured for 3 days. Control cells were kept in medium under the same conditions.
Orthotopic tumor model
Orthotopic tumor surgery was performed as previously described. 24 Briefly, mice were anesthetized intraperitoneally using a combination of 87 mg/kg ketamine hydrochloride (Ketanest S V R Pfizer Pharma, Berlin, Germany) and 13 mg/kg xylometazoline hydrochloride (Rompun V R Bayer HealthCare, Berlin, Germany). After opening the abdominal cavity and preparation of pancreas, a total volume of 20 mL containing equal amounts of cell suspension (2.5 3 10 5 DT6606PDA cells or 1 3 10 5 Panc02 cells) and matrigel (Matrigel TM Basement Membrane Matrix, BD Bioscience, San Jos e, CA) was injected into the head of the pancreas. Pancreas was then placed back and the abdominal cavity was closed by a running double-layer 4/0 polyester suture (Catgut, Marktneukirchen, Germany).
Infection with NDV R75/98 in vivo
Seven days after inoculation of the tumor mice were divided into two groups: the first group (n 5 5-8) received a 200 mL single dose of NDV strain R75/98 25 (4 3 10 6 PFU/mL) in PBS intravenously. The control group (n 5 3-5) received the same volume of PBS only.
For monitoring the effect of NDV on mice without tumor, 5 na€ ıve mice were infected with the same dose of NDV.
Analysis of tumor growth and infection rate
Mice were subjected to postmortem examinations at Day 2, Day 4, Day 7, Day 10, Day 14, Day 21, Day 56, and Day 100 after infection. The tumor was removed and measured by What's new? The dismal prognosis of pancreatic cancer has prompted investigation of alternative therapeutic avenues, one of which is the use of oncolytic viruses, which target cancer cells, proliferating specifically within them. Here, orthotopic implantation of two different pancreatic cancer cell lines (DT6606PDA and Panc02) in mice was used to evaluate immune activation following infection with Newcastle disease virus (NDV). While NDV successfully prompted an antitumor immune response in DT6606PDA tumors, initial tumor shrinkage in Panc02 mice was overtaken by relapse. The findings in DT6606PDA tumors suggest that direct oncolysis is followed by an adaptive immune response critical for long-term tumor rejection.
scale in length, width, and height to calculate volume (mm 3 ). Multiloculated tumors were dissected and volume of single tumors were summed up.
For determining infection of tumor cells, real-time PCR specific for the NDV-M gene was performed.
Flow cytometric analysis
At indicated time points blood, spleen, and mesenteric lymph nodes were removed, parts of the material were frozen in liquid nitrogen and fixed in paraformaldehyde (PFA), and the last part was prepared for FACS analysis according to established standardized procedures. 26 Briefly, single-cell suspension of spleen and lymph nodes was prepared using cell strainers with pore sizes of 1000 mm or 100 mm. Erythrocytes in blood samples were lysed with red blood cell lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 27 and TAP2, 28 respectively, R. SinE, a rabbit polyclonal Ab against human tapasin, 29 Horseradish peroxidase (HRP)-conjugated secondary antibodies (Dianova, Hamburg, Germany) were used. Bands were visualized with enhanced chemiluminescence substrate (Sigma Aldrich, Deisenhofen, Germany).
Immunofluorescence staining of frozen tumor sections
Frozen tumor samples were embedded in Tissue Freezing Medium (Jung, Leica Microsystems, Nussloch, Germany), cut in 3 mm thick sections and placed on Superfrost V R Plus microscope slides (Thermo Scientific, Braunschweig, Germany). After fixation in ice-cold acetone, infiltrating immune cells were stained using established standard protocols. 26 Briefly, tissue on slides was equilibrated to room temperature, blocked with 20% FCS in PBS for one hour and afterwards incubated with fluorescent dye-labelled antibodies directed against murine CD4 PE (clone GK1.5) and CD8 AlexaFluor 488 (clone 53-6.7, both BioLegend, Fell, Germany). After washing twice with PBS nuclei were counterstained with DAPI, slides were washed again and mounted with fluorescence mounting medium (DAKO, Glostrup, Denmark). Analyses were performed with an Axiovert 200 M/ApoTome microscope (Zeiss, Oberkochen, Germany) using the AxioVision software.
Detection of TGF-b1 in cell culture supernatant
For quantification of TGF-b1 in cell culture, supernatant of infected and control parental and reisolated Panc02 cells human/mouse TGF-b1 the ELISA ready-SET-Go!-Kit was used following the manufacturer's instructions (eBioscience, Frankfurt, Germany).
Statistics
In vitro and in vivo results were analyzed statistically and displayed graphically by using GraphPad Prism (version 5.0, GraphPad, San Diego, CA). * 5 p < 0.05 was considered as statistically significant.
Results
NDV inhibits tumor growth and mediates complete remission of DT6606PDA tumors in vivo but fails to prevent relapse in Panc02 tumor-bearing mice A single dose of NDV strain R75/98 was administered intravenously 7 days after tumor inoculation. As shown in the left panel of Figure 1a , already at d2 pi DT6606PDA tumor size of infected mice was smaller compared to the control group.
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Schwaiger et al. For the whole duration of the early phase (until d14 pi), this trend continued. Long-term tumor growth until d100 pi (right panel) was also monitored and no relapse of tumor in NDV infected mice could be observed, whereas tumors of untreated animals reached sizes of up to 3,800 mm 3 . Figure 1c illustrates that in the first week after NDV infection size of Panc02 tumors decreased rapidly, displaying even faster melting of tumors if compared with DT6606PDA tumors. Indeed, in the NDV-treated group tumors were macroscopically visible as early as d4 pi in 3 out of 5 mice and on d7 in only 2 out of 5 mice, compared to control tumors that already displayed an average size of 250 mm 3 . However, d14 pi tumors of NDV-infected mice reached a mean size of 490 mm 3 . The study had to be terminated prematurely for the control group at d14 pi and for NDV infected animals at d21 pi due to abortion criteria.
To determine infection of DT6606PDA cells, and thus a possible direct oncolytic effect of NDV on the cells, in vivo real-time RT-PCR for NDV-M was performed. In DT6606PDA-bearing mice only at d2 and d4 after infection with NDV viral genome was detected in the tumor, although values were close to the cut-off value of 38 (Fig. 1e ). In contrast, after infection of Panc02-bearing mice viral genome was not detected (data not shown).
Aberrant surface MHC I expression and induction of NK ligands in tumor cells makes them vulnerable for NK cellmediated lysis
To investigate both the general effect of NDV infection on the NK1.1 1 CD8 -leukocyte population as well as stimulation of these cells by NDV in tumor-bearing mice, FACS analyses of peripheral blood leucocytes (PBL) of na€ ıve mice (Fig. 2a , first middle panel) were performed 4 (upper panels) and 7 days (lower panels) after infection. Representative plots revealed that the total number of NK cells upon infection with NDV increased from 9.44% to 14.6% on d4 pi (first plot, upper panel) and 22.6% on d7 pi (first plot, lower panel). Frequency of NK cells in the blood of DT6606PDA tumor-bearing mice after NDV infection is increased to 14.6% on d4 pi (third plot, upper panel) compared to only tumor-bearing mice displaying 10.8% (second plot, upper panel) and increased further to 19.5% on d7 pi (third plot, lower panel), whereas in noninfected tumor-bearing mice percentages of NK cells in the blood remained unchanged (9.46%, second plot, lower panel). Inoculation of Panc02 tumor-bearing mice led to a decrease to 4.39% in circulating NK cells still detectable on d2 pi (fourth plot, upper panel) and was only restored to 11.9% due to NDV infection, which is comparable to na€ ıve mice (first middle plot). Until d7 pi NK cells in blood in Panc02 tumor-bearing mice infected with NDV returned to levels (fifth plot, lower panel) comparable to both noninfected Panc02 tumor-bearing mice (fourth plot, lower panel) and na€ ıve mice. Figure 2b shows statistical analysis.
Because the lack of surface MHC I leads to NK-mediated killing, we next analyzed whether the expression of MHC I and peptide loading complex (PLC) proteins (TAP1 and 2, as well as Tapasin) is aberrant in DT6606PDA and Panc02 cells. A strongly reduced expression of Tapasin and TAP2 was observed in DT6606PDA cells compared to the cell line DC-JAWS II serving as control (Fig. 2c) . Infection with NDVinduced Tapasin expression, although only at a low level. In Panc02 cells, expression of TAP2 could not be detected at all, whereas TAP1 is decreased compared to DC-JAWS II cells. 
NDV promotes tumor infiltration by T-cells in both tumor models leading to eradication of DT6606PDA but fails to prevent recurrence of Panc02 tumors
Because activation of NK and T-cells occurred upon viral infection in DT6606PDA tumor model (Figs. 2 and 3) , we set out to investigate whether these cells are able to infiltrate the tumor itself. Staining of cryosections of DT6606PDA tumor specimens revealed that the number of infiltrated CD8 1 (Fig. 4a, left pictures) as well as CD4 1 T-cells (right pictures) were significantly increased in the NDV treated group (lower pictures) compared to control animals (upper picture). Flow cytometric analysis of single cell suspension prepared from Panc02 tumors on d7 pi revealed that it was composed of 38.1% infiltrating leukocytes and 57.3% tumor cells in nontreated animals (Fig. 4b , left upper plot) and 80% leukocytes and 12.9% tumor cells in the NDV treated group (left lower plot). This ratio was shifted towards tumor cells in both groups until d14 pi as illustrated by representative plots (right plots). The bar graph depicts initially (d7 pi) disproportionally high amounts of infiltrating leukocytes in the NDV-treated group, which is balanced to a ratio of leukocytes to tumor cells to 1:1 on d14 pi in the NDV treated group. Further discrimination of infiltrating leukocytes revealed higher frequencies of CD8 1 (Fig. 4c , left graph) and CD4 1 T-cells (right graph) only on d7 in the NDV treated group, which did not last until d14 pi.
To determine the capacity of immune cells to eliminate Panc02 tumor cells, splenocytes from Panc02 tumor-bearing mice with and without NDV infection were isolated on d14 pi and subjected to an in vitro cytotoxicity assay (Fig. 4d) . Na€ ıve splenocytes (control: grey squares) caused specific lysis of 15% of cells at an effector to target cell ratio of 45:1, whereas a ratio of 90:1 of splenocytes isolated from Panc02 tumor-bearing mice 14 days after infection with NDV (black circles) was required to achieve the same specific lysis. However, splenocytes from Panc02 tumor mice that were not infected with NDV (white circles) completely lost their ability to eliminate Panc02 tumor cells in vitro.
Reisolated Panc02 cells displaying immunosuppressive properties and a nonimmunogenic phenotype
Because NDV infection led to a significant and rapid decrease in Panc02 tumor volume until d7 pi but failed to prevent recurrence even in the presence of a strong infiltrate, we investigated whether Panc02 tumor cells themselves had undergone changes that on the one hand might enable them to escape or inhibit an immune-cell attack and on the other hand had altered their susceptibility for a second infection with NDV. Flow cytometric analysis of Rae-1d revealed that in reisolated Panc02 tumor cells this NK ligand was barely detectable and furthermore expression could not be induced by NDV infection which strongly contrasts with parental cells (Fig. 5a, left graph) . Similar observations were made for MHC I surface expression on parental and reisolated Panc02 cells (Fig. 5b) . <10% of reisolated cells expressed MHC I, which reflects the situation in untreated parental Panc02 cells or rather untreated mice. In line with these findings, TGF-b in cell culture supernatants (Fig. 5b, left graph) was significantly increased from 2800 pg/mL secreted by parental cells to 3700 pg/mL secreted by reisolates. Notably, NDV infection was not able to reduce the amount of secreted TGF-b in reisolates to the level of parental cells. Flow cytometric analysis revealed that among reisolates twice as many cells as in parental Panc02 showed expression of FoxP3. Infection of parental cells with NDV led to a significant decrease in FoxP3 1 cells, whereas in reisolates NDV infection even increased FoxP3 expression (Fig. 5b, right graph) .
Western blot analyses were designed to investigate whether aberrant expression of MHC I was due to decreased expression of PLC proteins. As already seen in Figure 2a , TAP1 and 2 expressions were inducible in parental cells upon infection with NDV (Fig. 5c) . In reisolates two major observations were made: first, expression of TAP2 was increased in comparison to parental cells in nontreated cells but displayed a time-dependent decrease (reisolates d14 compared to reisolates from d21), whereas TAP1 was not markedly altered in reisolates in comparison to control. Similar findings were made for the expression of Tapasin. Second, after in vitro infection TAP2 was barely detectable in reisolates from d14 pi and even decreased further until d21. In contrast, expression of TAP1 increased upon infection with NDV in reisolates from d14. Reisolates from d21 however showed decreased TAP1 and Tapasin expression after infection, which demonstrated to be rather unaffected in reisolates from d14 pi.
Discussion
The results of in vivo study using DT6606PDA cells showed an arrest of tumor growth and prevented recurrence in a syngeneic, orthotopic tumor model upon systemic infection with NDV R75/98. This effect may initially have been achieved by direct oncolysis, as real-time PCR detected NDV genome up to 4 days after infection of tumor tissue, and tumor size decreased as early as two days after infection. However, also activation and proliferation of NK cells occurred already at d2 pi. Characterization of DT6606PDA cells revealed that expression of MHC I and PLC proteins was strongly reduced, which is in line with several other studies investigating (pancreatic) cancer cell lines. 30, 31 No or only weak expression of MHC I should lead to NK killing. As this killing needs licensing via ligands for activating receptors and because many tumors do not express these ligands, NK killing is often abrogated. 32, 33 In our model, the number of NK1.1 1 cells increased upon viral infection. Because the frequency of NKT cells in the population of peripheral blood leukocytes is <0.5%, 34 the observed increase is mainly caused by NK cells. In line with our findings, Jarahian et al. showed that the nonlytic NDV strain Ulster induces NK cell activation by enhanced expression of ligands for cytotoxic receptors NKp44 and NKp46. The authors provided evidence that the HN protein of NDV serves as a ligand for these receptors, leading to enhanced production of effector lymphokines. 35 Sui et al. confirmed these results and showed that a DNA vaccine construct encoding for membrane-anchored HN protein was able to promote an antitumor immune response in a model of nonsmall cell lung cancer (NSCLC). 36 Although NDV R75/98 did not show signs of enhanced replication in and spreading among tumor cells in parallel to steadily decreasing amounts of NDV genome, NK cells remained activated until Day 10 pi. In addition to viral proteins, infected DT6606PDA cells also respond to NDV infection with upregulation of Rae-1d, which serves as a ligand for the NK cell receptor NKG2D. 37 In a variety of other cancer types and cell lines Rae-1d or related proteins expressed by the retinoic acid early inducible gene family are upregulated and serve as activating ligands for NK cells. 38, 39 However, in DT6606PDA cells Rae-1d was only marginally expressed but inducible by NDV. In addition to the concept of NK cell killing via missing-self, Cerwenka et al. showed that NK cells are able to reject a MHC I expressing tumor provided that the tumor cells also express Rae-1d on the surface. 40 This in turn explains the enhanced NK cell activity in the DT6606PDA tumor model even though cells upregulated MHC I. NK mediated tumor lysis in our model occurs via ligation of both viral proteins with NKp44 or NKp46 and Rae-1d with NKG2D regardless of induced MHC I expression. In contrast, the lack of activated NK cells in noninfected mice contributes to persisting tumor growth. Control of viral infections is frequently due to engagement of cytotoxic T-cells which play a crucial role in eliminating infected cells. 41 As expected, in our DT6606PDA tumor model we also observed strong activation of CD8
1 T-cells upon viral infection, proliferation and subsequent infiltration of the tumor itself. It is tempting to speculate that the NDV-inducible levels of surface expressed MHC I on DT6606PDA cells are due to increased induction of TAP1-expression and could be functionally sufficient for mounting CD8
1 T-cell-mediated cytotoxicity against the tumor. Because immunogenicity decreases with insufficient presentation of peptides on MHC I molecules on the cell surface as a result of deficient TAP expression, 42 DT6606PDA tumors from noninfected mice grew steadily by evasion of Tcell-dependent elimination. These tumors not only showed a cytotoxic T-cell infiltrate to be activated but also helper Tcells. Several studies proved that CD4
1 T-cells participate in clearing viral infection as well as in preventing chronicity. 43, 44 Two studies by Knutson et al. and Takeshima et al. described the beneficial effect of tumor-infiltrating T-helper cells on cytotoxic T-cells leading to enhancement of their cytotoxic functions and thus reduction or even regression of tumors. 45, 46 In line with the findings of Marzo and colleagues, we observed a massive infiltration of CD4
1 T-cells into the tumor from d7 pi which indicates a supporting role for the maintenance of CD8 1 T-cell number and infiltration. 47 Even though the importance of an early NK-mediated lysis cannot be ruled out, induction of an adaptive antitumor immune response is responsible for rejection and prevention of relapse. The results of our study underline that enhanced viral replication is not necessarily the key determinant for an effective tumor therapy but rather the induction of an effective immune response, which was confirmed by Sobol et al.
48
Results observed upon NDV infection of Panc02 tumorbearing mice sharply contrasted with not only our model using DT6606PDA cells but also the results obtained by Koks and coworkers using NDV in an orthotopic murine glioma model with GL261 cells, 49 that were originally induced by 3-MCA and thus-like the Panc02 cell line-displayed a sarcomatoid phenotype. Beside the different organ of origin of tumor cells as well as implantation site, two major differences between our model and the glioma model may account for the different outcomes. First, Koks and colleagues used a sixfold higher dose of NDV, which was furthermore applied intratumorally that explains increased oncolysis, whereas in our model viral genome indeed was undetectable in tumors. These observations underline the impact of both dose and application route of NDV. Second, in contrast to our results, they observed a specific T-cell response upon induction of immunogenic cell death (ICD) in tumors that mediated longterm tumor surveillance. 49 In our Panc02 model initial tumor melting upon NDV infection was mediated by induction of NK cells as early as d2 pi but probably inhibited from d7 pi when tumors lack Rae-1d. The lack of Rae-1d in reisolates might be either due to missing expression or by shedding from the membrane. This shedding would lead to sustained engagement of this ligand to NKG2D which is known to mediate receptor internalization and degradation without inducing effector functions in NK cells. 50 NDV did neither lead to activation of T-cells nor increased frequencies of CD4 1 and CD8 1 T-cells (data not shown) which argues against an induction of antigen-specific response. This in turn might be due to a general immunosuppression, because inoculation of Panc02 tumors impaired activation of T-cells in general and set up an anti-inflammatory environment characterized by increased serum TGF-b levels (Supporting Information Fig. 1 ). The missing induction of adaptive immunity explains to some extent tumor recurrence and reveals the different influences mediated by implantation of different tumor cells on the immune system. Although at d7 pi also Panc02 tumors were strongly infiltrated and barely detectable, henceforth the remaining tumor cells prevailed again. An elegant study by Koebel and coworkers elucidated that recurrence of MCA induced tumors did not arise from constant transformation but the presence of occult cells that were held in check by the adaptive immune system. 51 We cannot exclude that Panc02 cells undergo transformation due to selection pressure mediated by NDV-activated immune cells, but it is rather the genetic instability and thus the heterogeneity among cells in a tumor in which upon selective pressure the nonimmunogenic variants grow out whereas immunogenic cells are eliminated by immune cells. 52 These reisolated Panc02 tumor cells were characterized by increased TGF-b secretion as well as FoxP3 expression, which mimics regulatory T-cell functions and is known to promote tumor immune evasion in pancreatic carcinoma. 53 There are three arguments that the concept of clonal growth of occult tumor cells seems to be applicable in our model. First, Panc02 cells are derived from 3-MCA induced tumors, second, a certain proportion of parental Panc02 expressed neither MHC I nor Rae-1d, and third, induction of the adaptive immune response is impaired by both inoculation of Panc02 cells and high amounts of TGF-b secreted by the outgrowing tumor, which effectively inhibit expression of effector proteins required for CTL-induced lysis.
The diagram in Figure 6a summarizes our results and the possible model of DT6606PDA tumor surveillance in NDV infected mice. Early tumor remission is mediated via direct oncolysis of tumor cells by NDV and accompanied by activation and subsequent proliferation of NK and T-cells that infiltrate the tumor and mediate cytotoxicity. Long-term tumor surveillance is probably due to the generation of a specific antitumor immune response by the adaptive immune system. Using Panc02 cells NDV infection initially induced an NK cell response that accounted for the rapidly decreasing tumors. From d7 pi occult tumor cells prevailed again displaying not only a nonimmunogenic phenotype but also actively inducing immunosuppression and thus preventing initiation of an adaptive, specific antitumor immune response. The contrasting outcomes using two different pancreatic cancer cell lines reflects and confirms the situation in patients with regard to differences in their immune status induced by the tumor as well as the heterogeneity and thus immunogenicity of the tumor itself. It also elucidates that by rejection and long-term surveillance of the tumor a specific antitumor immune response is possible. Because the immune system of cancer patients appears to be predominantly inhibitory and held in a difficult-to-activate state due to the tumor itself, adjusting the dose of NDV according to previous trials might be necessary to overcome this state and thus enable an adaptive immune response.
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